Bringing High Performance Diagnostics to the Patient’s Side

Recent News

October 24, 2023

Instanosis announces FDA Breakthrough Device designation for InstaStrip-Fentanyl Rapid Test

Instanosis Inc, a leading diagnostic company based in Philadelphia, is proud to announce that its innovative InstaStrip-Fentanyl Rapid Test has achieved the Breakthrough Device designation by the United States Food and Drug Administration (FDA). This notable designation recognizes the device’s potential to be a transformative tool in the fight against the opioid crisis.

The InstaStrip-Fentanyl Rapid Test is designed for the qualitative detection of fentanyl in human urine, with a cutoff value of 1.0 ng/mL, making it suitable for both prescription and over-the-counter (OTC) usage. This test is significant as fentanyl is the primary cause of overdose-related deaths in the United States.

“Rapid and accurate identification of fentanyl presence is crucial in preventing overdoses and making timely clinical decisions,” remarked Dr. Xiaofeng Xia, Chief Operating Officer of Instanosis. “InstaStrip-Fentanyl, when made available OTC, will serve as an indispensable tool for a wide range of individuals, from emergency care providers to friends and family members, allowing them to detect fentanyl swiftly and augment the lifesaving impact of OTC naloxone.” stated Dr. Ping Wang, Founder of Instanosis and Professor at the University of Pennsylvania.

With a cutoff of 1.0 ng/mL, InstaStrip-Fentanyl ensures users can detect fentanyl with lab-level sensitivity, offering rapid results that can be visually interpreted without equipment. Moreover, its accessibility and ease of use empower the general public to participate actively in overdose surveillance and early outbreak recognition, crucial steps in enhancing public health safety.

Achieving Breakthrough Device designation is a testament to Instanosis’s dedication to addressing urgent diagnostic needs. The program accelerates the review process and fosters active communication with the FDA, ensuring timely feedback and guidance. For a device to be considered under this program, it must provide a substantially more effective treatment or diagnosis for life-threatening diseases or conditions.

“We are thrilled with this designation, which underscores our unwavering commitment to address pressing diagnostic needs,” said Dr. Xia. “We are keen to collaborate closely with the FDA to ensure that this transformative diagnostic tool reaches those in need as soon as possible.”

The fentanyl crisis in America has reached alarming proportions, representing a dire public health threat that cannot be overstated. Originally developed for medical use as a powerful synthetic opioid, fentanyl has found its way to the streets, leading to a drastic surge in overdose deaths. In fact, fentanyl and its analogs are now responsible for the majority of opioid-related fatalities in the U.S. Its potency, up to 100 times stronger than morphine and about 50 times more powerful than heroin, makes even minute amounts lethal. The crisis is further exacerbated by fentanyl’s clandestine production and distribution, often mixed unknowingly with other drugs, leaving users unaware of its deadly presence. As communities, healthcare providers, and policymakers grapple with the mounting challenges, the urgency for effective solutions, such as rapid diagnostic tools, becomes increasingly evident.

First-Of-Its-Kind Technology

Instanosis has developed sophisticated technology to further advance the field of diagnostics. Our diagnostics are hundreds of times more sensitive than the state of the art, making us an ideal choice for clinical trials and disease diagnosis and monitoring.

About Us

Instanosis enables rapid and portable detection and quantitation of extremely low concentrations of biomarkers across many diseases. Our first-of-its-kind technology platforms are hundreds of times more sensitive than state-of-the-art, at much lower cost, leading to accurate and instantly actionable results and cost savings for research, clinical trials, disease diagnosis and monitoring.

Our Partners

We partner with other organizations around the globe to further advance our diagnostic technology.

Have any questions?

Instanosis Inc

1004 W 9th Avenue, 
King of Prussia, PA 19406
United States